TAMMY OSBORN: Open Payments
NPI 1184996019 · BLUE SPRINGS, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,742 in 93 payments from 27 companies in 2025. Trend: 2023 $1,785 · 2024 $1,738 · 2025 $1,742
Food & beverage: $1,742
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 21 | $351 |
| Lilly USA, LLC | 12 | $227 |
| Bayer Healthcare Pharmaceuticals Inc. | 13 | $205 |
| AstraZeneca Pharmaceuticals LP | 4 | $140 |
| Novartis Pharmaceuticals Corporation | 5 | $99 |
| Astellas Pharma US Inc | 5 | $97 |
| Novo Nordisk Inc | 5 | $90 |
| Abbott Laboratories | 3 | $67 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $58 |
| Supernus Pharmaceuticals, Inc. | 3 | $56 |
Products named: Kerendia, MOUNJARO, VRAYLAR, AIRSUPRA, UBRELVY, LEQVIO, Veozah, QULIPTA.
Industry payments across MO — which companies pay providers there.
